Open AccessTriggering Receptor Expressed on Myeloid Cells in Cutaneous Melanoma
Author(s) -
Nguyen Austin Huy,
Koenck Carleigh,
Quirk Shan K.,
Lim Victoria M.,
Mitkov Mario V.,
Trowbridge Ryan M.,
Hunter William J.,
Agrawal Devendra K.
Publication year - 2015
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12308
Subject(s) - myeloid cells , melanoma , cancer research , myeloid , receptor , medicine , biology , computational biology
The tumor microenvironment plays an important role in the progression of melanoma, the prototypical immunologic cutaneous malignancy. The triggering receptor expressed on myeloid cells (TREM) family of innate immune receptors modulates inflammatory and innate immune signaling. It has been investigated in various neoplastic diseases, but not in melanoma. This study examines the expression of TREM‐1 (a proinflammatory amplifier) and TREM‐2 (an anti‐inflammatory modulator and phagocytic promoter) in human cutaneous melanoma and surrounding tissue. Indirect immunofluorescence staining was performed on skin biopsies from 10 melanoma patients and staining intensity was semiquantitatively scored. Expression of TREM‐1 and TREM‐2 was higher in keratinocytes than melanoma tissue (TREM‐1: p < 0.01; TREM‐2: p < 0.01). Whereas TREM‐2 was the dominant isoform expressed in normal keratinocytes, TREM‐1 expression predominated in melanoma tissue (TREM‐1 to TREM‐2 ratio: keratinocytes = 0.78; melanoma = 2.08; p < 0.01). The increased TREM ratio in melanoma tissue could give rise to a proinflammatory and protumor state of the microenvironment. This evidence may be suggestive of a TREM‐1/TREM‐2 paradigm in which relative levels dictate inflammatory and immune states, rather than absolute expression of one or the other. Further investigation regarding this paradigm is warranted and could carry prognostic or therapeutic value in treatment for melanoma.